Evidence map›Paper›PMID 42405762›Full record

ArticleMicrobiology spectrum2026

Impact of nonalcoholic fatty liver disease on the response to pegylated interferon-α therapy in patients with chronic hepatitis B.

Huiqing Liang, Yizhi Xie, Yan Dai, Xiaorong Yang, Xiaoting Zheng, Jiaen Yang, Yaoyu Liu, Chuncheng Wu, Siyan Chen, Manying Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huiqing Liang *Hepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Yizhi Xie *School of Clinical Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.ORCID 0009-0007-9764-5428
Yan Dai *School of Clinical Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Xiaorong YangHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Xiaoting ZhengHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Jiaen YangHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Yaoyu LiuHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Chuncheng WuHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Siyan ChenSchool of Clinical Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Manying ZhangHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.
Hongli ZhuangDepartment of Traditional Chinese Medicine, No.1 Hospital, Xiamen University, Xiamen, Fujian, China.
Li LinHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China.ORCID 0009-0009-5814-908X
Shaodong ChenDepartment of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen, Fujian, China.ORCID 0009-0009-2283-0586

Funding

Fujian Provincial Department of Science and Technology 2023J011636, 2025ZDB001The National Natural Science Foundation of China 82374353Xiamen Municipal Bureau of Science and Technology 3502Z20224018
6 · The paper itself

Abstract

Hepatitis B surface antigen (HBsAg) clearance is regarded as the optimal therapeutic endpoint in patients with chronic hepatitis B (CHB). Pegylated interferon-α (PegIFNα) is currently one of the most effective strategies for achieving this goal. However, the impact of concurrent nonalcoholic fatty liver disease (NAFLD) on the PegIFNα treatment response in CHB patients remains controversial. The aim of this study was to investigate the impact of NAFLD on the antiviral efficacy of PegIFNα in patients with CHB and identify baseline predictors of HBsAg clearance. In this retrospective cohort study, 201 CHB patients receiving PegIFNα monotherapy or PegIFNα in combination with nucleos(t)ide analogs were enrolled and stratified into CHB-only (

Indexed as

Antiviral AgentsHepatitis B, ChronicInterferon-alphaNon-alcoholic Fatty Liver DiseasePolyethylene GlycolsAdultDrug Therapy, CombinationFemaleHepatitis B Surface AntigensHepatitis B virusHumansMaleMiddle AgedRecombinant ProteinsRetrospective StudiesTreatment OutcomeAntiviral AgentsHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsRecombinant Proteinschronic hepatitis BHBsAg clearancenonalcoholic fatty liver diseasepegylated interferon-alphapredictors

Identifiers

PMID42405762
PMCPMC13436357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.